[Serum levels of intact molecular osteocalcin in children with growth hormone (GH) deficiency during GH therapy: an early predictor of GH therapy].

Recently we developed a sandwich enzyme immunoassay (EIA) specific for intact molecular osteocalcin (I-OC), produced only by osteoblast cell and partially released into blood circulation, to establish a specific biochemical marker of bone formation. In order to confirm whether serum I-OC levels constitute a specific marker for bone formation and to assess the relationship between serum I-OC levels and growth response to growth hormone (GH) therapy, we measured the serum I-OC in serial serum samples using this EIA from 61 children with GH deficiency who showed significant bone growth during GH therapy. The serum I-OC levels in children with GH deficiency before GH therapy were slightly lower than those in normal children (Kanzaki S. et al., J. Clin Endocrinol Metab. 1992;75:1104-9), and had a wide distribution overlapped with the normal range. These levels were apparently increased during GH treatment; that is, in contrast to the levels of 22.9 +/- 1.5 ng/ml (mean +/- SE) before GH treatment, the levels after 1 and 2 months of GH treatment were 29.1 +/- 1.6 ng/ml and 32.5 +/- 1.8 ng/ml, respectively. However, they decreased slightly at 3 months and then they gradually rose to 37.5 +/- 2.8 ng/ml after 12 months, I-OC ratios, represented by the I-OC level at each month of GH therapy in relation to pretreatment level, correlated well with the growth response (growth velocity, growth velocity SD score and delta growth velocity SD score) after 12 months of GH treatment. Correlation coefficients of the growth velocity versus I-OC ratio at 1 and 6 months of GH treatment were 0.677 (p < 0.001, N = 58) and 0.752 (p < 0.001, N = 55), respectively. However, both IGF-I and ALP ratios represented in the same way as the I-OC ratio, correlated poorly as compared with the I-OC ratio. These results demonstrate that the change of serum I-OC levels indicates a direct and sensitive reflection of bone formation, because serum I-OC levels significantly increased with the growth response to GH therapy. The measurement of serum I-OC levels after 1 month of GH treatment may be a useful tool in predicting improved growth velocity during long-term GH therapy.

[1]  S. Kanzaki,et al.  Secretion of osteocalcin and its propeptide from human osteoblastic cells: Dissociation of the secretory patterns of osteocalcin and its propeptide , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Shiraki,et al.  Sandwich immunoassay for intact human osteocalcin. , 1992, Clinical chemistry.

[3]  Hiroyuki Tanaka,et al.  Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: a potential marker of bone growth and response to GH therapy. , 1992, The Journal of clinical endocrinology and metabolism.

[4]  L. Tatò,et al.  Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency. , 1991, The Journal of pediatrics.

[5]  A. Sartorio,et al.  Serum Osteocalcin Levels in Patients with GH Deficiency before and during GH Treatment , 1991, Acta paediatrica Scandinavica.

[6]  C. Christiansen,et al.  Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. , 1990, The Journal of clinical endocrinology and metabolism.

[7]  S. Mohan,et al.  Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. , 1990, The Journal of clinical endocrinology and metabolism.

[8]  J B Lian,et al.  Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.

[9]  H. Tanaka,et al.  Cooperation of synthetic insulin-like growth factor I/somatomedin C and 1,25-dihydroxyvitamin D3 on regulation of function in clonal osteoblastic cells. , 1989, Bone and mineral.

[10]  N. Katsumata,et al.  Serum insulin-like growth factor I (somatomedin-C) level in normal subjects from infancy to adulthood, pituitary dwarfs and normal variant short children. , 1988, Endocrinologia japonica.

[11]  N. Skakkebaek,et al.  Serum bone Gla-protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I, and serum testosterone. , 1988, The Journal of clinical endocrinology and metabolism.

[12]  M. Rechler,et al.  Hormonal regulation of human growth. , 1987, The New England journal of medicine.

[13]  P. Delmas,et al.  Serum bone GLA‐protein in growth hormone deficient children , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  R. Weinstein,et al.  Multiple immunoreactive forms of osteocalcin in uremic serum. , 1986, The Journal of clinical investigation.

[15]  M. Mizruchi,et al.  Osteocalcin in human serum: a circadian rhythm. , 1985, The Journal of clinical endocrinology and metabolism.

[16]  L. Deftos,et al.  New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. , 1980, The Journal of clinical investigation.

[17]  P. Price,et al.  Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Saggese,et al.  Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. , 1993, The Journal of pediatrics.